LIVE

GILD

Gilead Sciences, Inc.

GILD

NASDAQ·Healthcare·Drug Manufacturers - General·Mkt cap $156.4B

$130.22

▲ +3.37%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$107.75 - $157.29

P/E

17.74

Fwd P/E

14.81

Beta

0.33

Div Yield

2.56%

Avg Vol

7.1M

Shares Out

1.2B

Mkt Cap

$156.4B

Price action

Price chart

Up 13.0% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

5 reasons

  • Extensive portfolio of FDA-approved blockbuster drugs with strong market positions
  • Established global distribution network and manufacturing capabilities
  • Strategic partnerships with leading biotech and pharmaceutical companies
  • Significant R&D pipeline and expertise in virology and immunotherapy
  • Strong cash flows enabling continued investment in innovation
▼

Bear Case

1 risk

  • Low volatility (beta 0.3).

Growth

Stable outlook

Expansion of HIV treatment market with next-generation antiretroviral therapies

Value

Fairly valued vs Large Cap Pharma peers

Momentum

Weak

-9.8% over 3m

Quality

Excellent

Excellent business quality

Dividend

Solid

2.56% yield

Earnings track record

Latest print - beat on both lines

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Apr 22, 2026

“
Q2 26 RECAP

MAY 7, 2026

Reported EPS of $2.03 vs $1.91 consensus (+6.3% surprise). Revenue of $7.0B vs $6.9B expected (+0.7%). Beat on both top and bottom lines.

EPS beat +6.3%
Rev beat +0.7%
Double beat

EPS surprise · last 4Q

1 of 1 beats

Q2 26

+6.3%

Next: Apr 22, 2026

Revenue trend · last 8Q

—

—

+6%

-0%

+2%

+3%

+5%

+4%

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$7.0B

$7.5B

$7.6B

$6.7B

$7.1B

$7.8B

$7.9B

$7.0B

Margins · last 8Q

Gross

79.2%

Operating

37.2%

Profit

29.0%

View full earnings history →

Wall Street consensus

9 analysts · 89% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

8

89%

Hold

1

11%

Sell

0%

Median Price Target

$165.00

▲ +26.7% vs $130.22

Low $155.00
Median $165.00
High $175.00

Latest: RBC Capital · Jun 8, 2026

3 analysts covering

View full analyst page →

vs Industry

How GILD stacks vs Drug Manufacturers - General

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.